This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
lower gastrointestinal tract motility regulators
Acts as a spasmolytic.
Absorption: Rapidly absorbed following oral administration.
Metabolism and Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.
Half-life: 2.7–3.1 hr.
TIME/ACTION PROFILE (symptom relief)
|PO||within 3 days–2 wk||1 hr (blood level)||>1 wk (following discontuation)|
Use Cautiously in:
CNS: dizziness, drowsiness, fatigue, headache
GI: diarrhea, dry mouth, dysguesia, dyspepsia, epigastric pain, nausea
Derm: hot/cold sensation, rash
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults): 200 mg 3 times daily.
Tablets: 100 mg, 200 mg
Decrease signs and symptoms of irritable bowel disease.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.